Drug recall · June 20, 2018
Maxzide-25 recall
Why: Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01
- Lots / codes
Lot #: 3087136, Exp 5/20
- Quantity
- 1,620 bottles
- Company
- Mylan Pharmaceuticals Inc., Morgantown, WV
- Distribution
- Product was distributed throughout the United States
- Initiated
- June 7, 2018 · Voluntary: Firm initiated
- Classified
- June 15, 2018
- Reported
- June 20, 2018
- Ended
- June 20, 2019
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hydrochlorothiazide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.